OverviewSuggest Edit

Genfit SA, a biopharmaceutical company, develops therapeutic and diagnostic solutions to address high unmet patient needs in metabolic and inflammatory diseases with a focus on the liver and gastroenterology worldwide. It offers diagnostic solutions in various therapeutic areas, such as metabolic diseases, liver diseases, non-alcoholic steato-hepatitis (NASH), cholestatic liver diseases, inflammation and autoimmune diseases, and inflammatory bowel diseases. The company’s lead pipeline product comprises GFT505, which is in Phase II clinical trials for the treatment of NASH. It is also developing TGFTX1 program that targets the RORgamma-t receptor, which directs IL-17 mediated immunity to treat inflammatory and auto-immune diseases; and TGFTX3 program for developing proprietary compounds, which activate the nuclear receptor Rev-Erba for metabolic and inflammatory diseases, including NASH and type 2 diabetes. The company also develops TGFTX4 program that inhibits the proliferation and the pro-fibrotic activation of primary human hepatic stellate cells; TGFTX5 program for chronic inflammatory bowel diseases; and SAN/GFT-2 program to develop molecules, which correct the mitochondrial dysfunction associated with certain pathologies comprising type 2 diabetes and kidney diseases. Genfit SA was founded in 1999 and is headquartered in Loos, France.
TypePublic
Founded1999
HQLoos, FR
Websitegenfit.com

Latest Updates

Employees (est.) (Jul 2021)130
Job Openings2
Revenue (FY, 2020)€7.8 M(-81%)
Share Price (Nov 2021)€3.2
Cybersecurity ratingAMore
Discover new suppliers and conduct deeper comparison analysis with Craft for EnterpriseLearn more
Banner background

Key People/Management at Genfit

Jean-Francois Mouney

Jean-Francois Mouney

Chairman of the Board of Directors and Chief Executive Officer of GENFIT, Co-Founder
Ph. D Dean Hum

Ph. D Dean Hum

Senior Executive VP and Chief Scientific Officer (CSO)
Nathalie Huitorel

Nathalie Huitorel

Executive VP and Chief Financial and Administrative Officer (CFO)
Sophie Megnien

Sophie Megnien

Chief Medical Officer (CMO)
Jean-Christophe Marcoux

Jean-Christophe Marcoux

Chief Strategy Officer
Laurent Lannoo

Laurent Lannoo

Corporate Secretary, Director of Legal Affairs
Show more

Genfit Office Locations

Genfit has offices in Loos and Cambridge
Loos, FR (HQ)
885 Avenue Eugène Avinée
Cambridge, MA, US
1 Alewife Center Suite 220
Show all (2)

Genfit Financials and Metrics

Genfit Revenue

Genfit's revenue was reported to be €7.76 m in FY, 2020
EUR

Revenue (FY, 2020)

7.8m

Net income (FY, 2020)

(101.2m)

EBIT (FY, 2020)

(82.9m)

Market capitalization (10-Nov-2021)

146.3m

Closing stock price (10-Nov-2021)

3.2

Cash (31-Dec-2020)

171.0m

EV

(12.8m)
Genfit's current market capitalization is €146.3 m.
EURFY, 2017FY, 2018FY, 2019FY, 2020

Revenue

6.9m7.5m41.0m7.8m

Revenue growth, %

9%

General and administrative expense

9.4m9.8m

R&D expense

54.2m67.0m
EURFY, 2017FY, 2018FY, 2019FY, 2020

Cash

273.8m207.2m276.7m171.0m

Accounts Receivable

8.0m8.8m

Inventories

4.0k4.0k4.0k4.0k

Current Assets

283.6m218.1m290.8m184.7m
EURFY, 2017FY, 2018FY, 2019FY, 2020

Net Income

(55.7m)(79.5m)(65.1m)(101.2m)

Depreciation and Amortization

1.4m1.6m3.3m3.6m

Accounts Payable

7.4m11.1m

Cash From Operating Activities

(49.9m)(56.1m)(47.7m)(96.4m)
EURFY, 2017

EV/EBIT

-7.8 x

EV/CFO

-8.8 x

Revenue/Employee

59.1k

Financial Leverage

2.9 x
Show all financial metrics

Genfit Operating Metrics

Apr, 2018FY, 2019

Patent Applications (US)

11

Patents (Foreign)

450

Patents (US)

28

Phase III Patients Enrolled

1 k
Show all operating metrics

Genfit Acquisitions / Subsidiaries

Company NameDateDeal Size
Genfit Corp.
Genfit Pharmaceuticals SAS

Genfit Cybersecurity Score

Cybersecurity ratingPremium dataset

A

91/100

SecurityScorecard logo

Genfit Environment, Social & Governance (ESG) Ratings

CSRHub ESG ratingPremium dataset

40-49

out of 100

CSRHub logo

Genfit Online and Social Media Presence

Embed Graph

Genfit News and Updates

Is Genfit Primed to Win the NASH Derby?

Investors are watching the changing fortunes of the drug companies in the race to successfully commercialize the first drug for NASH, or nonalcoholic steatohepatitis. Genfit is in a secure financial position as it proceeds to a phase III trial for its NASH entrant.

Asia-Pacific Nonalcoholic Steatohepatitis Therapeutics Markets Report 2018-2024 Featuring Key Players - Allergan, Galmed, Genfit, Gilead, Intercept Pharmaceuticals & Zydus

DUBLIN, Jan. 16, 2019 /PRNewswire/ -- The "Nonalcoholic Steatohepatitis Therapeutics in Asia-Pacific Markets to 2024 - Launch of NASH-Specific Premium Products and Rising Prevalence to Drive the Market" report has been added to ResearchAndMarkets.com's offering. The NASH Asia-Pacific...
Show more

Genfit Blogs

GENFIT: FNIH NIMBLE Study Demonstrates NIS4® Technology’s Unique Performance in Identifying Patients with “at-risk” NASH

Lille, France; Cambridge, M A ; November 18 , 2021 - GENFIT (Nasdaq and Euronext: GNFT) , a late-stage biopharmaceutical company dedicated to improving the lives of patients with metabolic and chronic liver diseases, is proud to announce that NIS4® technology’s utility has been recognized in a

New Clinical Data on GENFIT’s Investigational Compound Elafibranor to be Presented at AASLD The Liver Meeting®

New Clinical Data on GENFIT’s Investigational Compound Elafibranor to be Presented at AASLD The Liver Meeting® Content Import Tue, 11/02/2021 - 17:10 New Clinical Data on GENFIT’s Investigational Compound Elafibranor to be Presented at AASLD The Liver Meeting® November 2, 20…

GENFIT Reports First Half-Year 2021 Financial Results and Provides Corporate Update

GENFIT Reports First Half-Year 2021 Financial Results and Provides Corporate Update Financial highlights Cash and cash equivalents totaled € 104 million as of June 30, 2021 (including €11 million non-dilutive financing obtained in the first half 2021 ) Net income totaled € 9 million for the first

GENFIT: Half-Year Report of Liquidity Contract with Crédit Industriel et Commercial

GENFIT: Half-Year Report of Liquidity Contract with Crédit Industriel et Commercial Content Import Fri, 07/09/2021 - 16:10 GENFIT: Half-Year Report of Liquidity Contract with Crédit Industriel et Commercial July 9, 2021 This release is a backfill from a News …

GENFIT: June 30, 2021 Annual Shareholders Meeting results

GENFIT: June 30, 2021 Annual Shareholders Meeting results Content Import Wed, 06/30/2021 - 16:11 GENFIT: June 30, 2021 Annual Shareholders Meeting results June 30, 2021 This release is a backfill from a News Wire News / Actualités …

GENFIT obtains non-dilutive financing of €11 million in the form of a State Guaranteed Loan

Lille, France; Cambridge, M A ; June 24 , 2021 - GENFIT (Nasdaq and Euronext: GNFT) , a late-stage biopharmaceutical company dedicated to improving the lives of patients with metabolic and liver diseases, today announced the securing of a €11 million non-dilutive loan guaranteed by the French
Show more

Genfit Frequently Asked Questions

  • When was Genfit founded?

    Genfit was founded in 1999.

  • Who are Genfit key executives?

    Genfit's key executives are Jean-Francois Mouney, Ph. D Dean Hum and Nathalie Huitorel.

  • How many employees does Genfit have?

    Genfit has 130 employees.

  • What is Genfit revenue?

    Latest Genfit annual revenue is €7.8 m.

  • What is Genfit revenue per employee?

    Latest Genfit revenue per employee is €59.7 k.

  • Who are Genfit competitors?

    Competitors of Genfit include Ablynx, Promethera Biosciences and Iceni Diagnostics.

  • Where is Genfit headquarters?

    Genfit headquarters is located at 885 Avenue Eugène Avinée, Loos.

  • Where are Genfit offices?

    Genfit has offices in Loos and Cambridge.

  • How many offices does Genfit have?

    Genfit has 2 offices.